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We would like to add another possible mechanism that may explain the beneficial effect of rituximab on minimal-change nephrotic syndrome (MCNS). Although rare, some reports have shown that Th2 cytokines, such as interleukin (IL)-13, may play an important role in the pathogenesis of MCNS. [2] [3] [4] Yap et al. reported that CD4 + and CD8 + IL-13 mRNA expression was increased in patients with nephrotic relapse compared with those in remission, healthy individuals, and patient controls (children with viral infections, but without idiopathic nephrotic syndrome; P <0.008) and that this finding was related to an increase in expression of cytoplasmic IL-13 in phorbol myristate acetate/ionomycin-activated CD3 + cells (6.66 ± 3.39%) in patients with nephrotic relapse compared with expression in patients in the remission phase (2.59 ± 1.35%, P <0.0001). 2 Yap et al. speculated that IL-13 may act on monocytes to produce vascular permeability factors Effect of rituximab in MCNS: a role for IL-13 suppression?
Ji Eun Kim, Se Jin Park, Tae-Sun Ha and Jae Il Shin involved in the pathogenesis of proteinuria in patients with relapse of nephrotic syndrome. 2 Cheung et al. also showed that the percentage of CD3 + IL-13-producing cells was significantly increased in children with nephrotic relapse, and correlated with serum IgE levels during the active phase of the disease (r = 0.90, P <0.001). 3 In addition, Lai et al. have demonstrated that IL-13-transfected rats (n = 41) show a minimal-change-like nephropathy (charac terized by increased proteinuria, hypo albuminaemia and hypercholesterolaemia) compared with control rats (n = 17). 4 In their study, the glomeruli of rats transfected with IL-13 showed no significant histologic changes, but electron microscopy findings showed that up to 80% of podocyte foot processes showed fusion and that glomerular gene expression of B7-1, IL-4Rα and IL-13Rα2 were upregulated, whereas those of nephrin, podocin and dystroglycan were downregulated. 4 Although not in the setting of MCNS, another study has shown that rituximab could reduce levels of IL-13 expressing T cells. 5 Simon et al. showed that the numbers of cytokine-expressing CD4 + and CD8 + T cells were reduced with a relative decrease in the mRNA expression of IL-5 (mean 53%) and IL-13 (mean 83%) after rituximab therapy in patients with moderate to severe atopic dermatitis not responding to topical corticosteroid and/or calcineurin inhibitor therapy. 5 So there is a possibility that rituximab might be beneficial in MCNS by suppression of IL-13, which could be involved in the development of MCNS, in addition to depletion of B cells. However, further studies are necessary to evaluate serial changes in levels of IL-13 after rituximab treatment in MCNS and to elucidate the exact role of IL-13 in the pathogenesis of MCNS.
